ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Proteomic characterization of airway obstruction-associated proteins in non-smoking lung adenocarcinoma.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) and chronic airway obstruction frequently coexist and are associated with poorer clinical outcomes. Although airway obstruction is recognized as a risk factor for adverse prognosis in LUAD, the molecular alterations associated with airway obstruction in LUAD remain incompletely understood. Most previous studies have been confounded by smoking-related molecular changes.
objectiveTo identify proteins associated with airway obstruction status in non-smoking patients with LUAD using a proteomics-based approach.
methodsProteomic analysis was performed on paired tumor and adjacent normal tissues obtained from 12 non-smoking LUAD patients, including 6 patients with airway obstruction and 6 without airway obstruction. A four-group design combined with a three-step intersection strategy was used to identify candidate proteins associated with both airway obstruction status and tumor-related alterations. Functional enrichment, protein-protein interaction (PPI) network analysis, Western blot validation, correlation with pulmonary function, and transcriptomic validation using The Cancer Genome Atlas (TCGA) database were subsequently performed.
resultsA total of 2036 differentially expressed proteins were identified in tumor tissues between airway obstruction and non-obstruction groups. The three-step intersection strategy identified 15 candidate proteins. PPI network analysis and expression-direction consistency screening further identified four core proteins: Cystatin B (CSTB), Bone Morphogenetic Protein Receptor Type 1A (BMPR1A), Complement C4B (C4B), and Potassium Channel Tetramerization Domain Containing 10 (KCTD10). Western blot validation supported the differential expression patterns of these four core proteins in tumor tissues. Functional enrichment analysis indicated involvement in DNA damage repair, immune regulation, and cellular proliferation pathways. CSTB expression was positively correlated with FEV1%, whereas BMPR1A expression showed a negative correlation. TCGA analyses demonstrated that expression of these proteins' corresponding genes was associated with LUAD prognosis, and C4B expression was significantly associated with tumor stage.
conclusionsThis study identified CSTB, BMPR1A, C4B, and KCTD10 as proteins associated with airway obstruction status in non-smoking LUAD patients. These findings provide preliminary insights into molecular differences related to airway obstruction in LUAD and generate candidate biomarkers for future validation studies. Western blot validation provided additional experimental support for the proteomic findings. Larger multicenter cohorts and functional experiments are required to clarify the biological and clinical significance of these proteins.
Indexed as
Identifiers
42472420What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.